RPG Life Sciences FY25: Profit doubles, ₹24 dividend

Key takeaway from FY25 results

RPG Life Sciences Ltd. reported a sharp improvement in FY25 profitability, helped by stronger operating performance and a large exceptional gain tied to the assignment of surplus leasehold land in Navi Mumbai. The board also recommended its highest-ever payout, combining a final dividend and a special dividend.

For the year ended March 31, 2025, the company reported total income of ₹666.11 crore, up from ₹589.26 crore in FY24. Profit for the year after tax stood at ₹183.24 crore versus ₹87.66 crore a year earlier. Other comprehensive income (net of tax) was negative at ₹(1.10) crore in FY25 compared with ₹(0.56) crore in FY24, taking total comprehensive income to ₹182.14 crore.

FY25 income and profit growth in numbers

The company’s annual report-style table for FY25 showed profit before depreciation, interest and tax at ₹172.33 crore, up from ₹135.36 crore in FY24. Interest expense remained low at ₹0.62 crore in FY25 versus ₹0.45 crore in FY24.

In another FY25 disclosure included in the provided material, revenue from operations was stated at ₹653.43 crore, up from ₹582.05 crore in FY24, a 12% year-on-year rise. Profit before tax (PBT) before exceptional items was reported at ₹150.28 crore versus ₹117.84 crore in FY24.

Exceptional gain from land assignment

A key driver for reported profitability was a one-time gain linked to the assignment of surplus vacant leasehold land with built-up structures at MIDC, Navi Mumbai. The material states an exceptional profit of ₹109.90 crore from this land assignment.

It also notes that the transaction involved an exceptional gain of ₹126.23 crore, while the company incurred a loss of ₹16.33 crore on account of a fire during the period. Separately, the company highlighted that cash surplus rose materially when exceptional items were included.

Dividend: ₹20 final plus ₹4 special

For FY25, the directors recommended a dividend of ₹20 per share (250%) and an additional special dividend of ₹4 per share (50%) on account of the significant exceptional profit from land assignment. This takes the total recommended dividend to ₹24 per share, subject to shareholder approval at the ensuing annual general meeting.

For context, the FY24 disclosure in the provided text references a recommended dividend of ₹16 per equity share (200%) on face value of ₹8 each.

Q4FY25 performance and the one-time boost

For Q4FY25, revenue from operations was reported at ₹143.09 crore, up from ₹126.99 crore in Q4FY24, a 13% year-on-year increase. Net profit surged to ₹117.35 crore in Q4FY25 versus ₹13.24 crore in Q4FY24, reflecting the impact of exceptional items.

The Q4FY25 EBITDA was reported at ₹30.55 crore compared with ₹14.23 crore a year earlier, with EBITDA margin at about 21% versus about 11%. PBT before exceptional items for Q4FY25 was stated at ₹25.00 crore versus ₹17.74 crore in Q4FY24.

Segment notes: domestic formulations remains central

The provided material repeatedly points to domestic formulations as the primary growth engine. One disclosure states domestic formulations revenue of ₹425.00 crore in FY25, up 10.1% year-on-year, supported by higher prescription generation, new launches and line extensions, and tighter control on sales hygiene and inventories.

Therapy expansion was also highlighted, with new launches across Cardiovascular, Diabetology, Nephrology, Rheumatology, Oncology and Urology, and entry into clinical Dermatology, Orthopedic and Critical Care segments.

Cash surplus and margin commentary

Management commentary included in the material states that the company built a sizeable cash surplus of about ₹163.7 crore from operations, and around ₹266 crore when exceptional items are included. In the same set of remarks, FY25 margin expansion is described as continuing, with EBITDA margin moving up from 23% to 26% year-on-year.

Another set of FY25 highlights specifies EBITDA margin expansion from 23.3% to 26.4% year-on-year.

Update from FY26: Q2 and H1 figures, plus fire incident

The provided text includes H1 FY26 and Q2 FY26 disclosures. RPG Life Sciences reported domestic formulations growth of 13.5% during H1 FY26, compared with the Indian pharmaceutical market’s 7.4% growth. Domestic formulations contributed 71% to total sales in H1 FY26, according to the same material.

For Q2 FY26, one table reports revenue from operations at ₹181.70 crore versus ₹172.20 crore in Q2 FY25. EBITDA was ₹43.60 crore versus ₹47.90 crore, and PAT was ₹28.50 crore versus ₹31.50 crore.

A separate Q2 FY26 table (presented in ₹ lakh) reports revenue from operations of ₹181.68 crore and PAT of ₹36.85 crore, along with exceptional income of ₹11.22 crore related to insurance proceeds from a fire incident at a manufacturing block in January 2025. The material also notes that APIs declined 34.2% to ₹34.50 crore in H1 FY26 due to the fire incident.

Stock reaction and market snapshot

Following the Q4FY25 and FY25 disclosure, shares of RPG Life Sciences closed 6.01% lower at ₹2,108.80 on the BSE, while the Sensex rose 1.27%, according to the provided text.

The dataset also includes a market snapshot listing market capitalisation at ₹3,141 crore, current price at ₹1,899, 52-week high/low at ₹2,725/₹1,772, P/E at 29.9, book value at ₹335, dividend yield at 1.04%, ROCE at 32.8%, ROE at 25.5% and face value at ₹8.

Key numbers table

Why this matters for investors

The FY25 print highlights how a strong quarter and a large exceptional gain can significantly change headline profitability and payout capacity. At the same time, the recurring trend the company emphasised is domestic formulations growth that is reported as higher than the broader market, supported by portfolio expansion into multiple therapies.

The FY26 interim disclosures add a second layer to the story: a fire incident affected API performance, while insurance proceeds were reported as exceptional income in Q2 FY26. In parallel, the company’s profitability metrics in Q2 FY26 show mixed movement across different tables included in the material, underscoring the need for investors to reconcile quarterly presentation and exceptional items while tracking core operating performance.

Conclusion

RPG Life Sciences’ FY25 results combined higher income with a sharp rise in reported profits, supported by a major exceptional gain from land assignment, and led to a recommended total dividend of ₹24 per share. The next key checkpoints are shareholder approval for the dividend and subsequent quarterly updates on domestic formulations growth and the API business after the reported fire-related disruption.